{
  "risk_summary_version": "2.1",
  "risk_management_file_ref": "RMF-CSX-2023-R3",
  "last_review_date": "2023-12-20",
  "hazard_rows": [
    {
      "hazard_id": "HZ-001",
      "hazard_name": "Stent migration post-deployment",
      "harm": "Vessel occlusion requiring emergency intervention",
      "severity": 5,
      "probability": 1,
      "risk_level": "MEDIUM",
      "residual_risk_level": "LOW",
      "mitigation": "Deployment pressure guidelines, radiopaque markers for positioning verification",
      "last_reviewed": "2023-12-15"
    },
    {
      "hazard_id": "HZ-002",
      "hazard_name": "Polymer coating delamination",
      "harm": "Acute stent thrombosis",
      "severity": 5,
      "probability": 1,
      "risk_level": "HIGH",
      "residual_risk_level": "LOW",
      "mitigation": "Coating adhesion QC testing per lot, accelerated aging validation",
      "last_reviewed": "2023-12-15"
    },
    {
      "hazard_id": "HZ-003",
      "hazard_name": "Delivery system balloon rupture",
      "harm": "Procedure failure requiring repeat catheterization",
      "severity": 3,
      "probability": 2,
      "risk_level": "MEDIUM",
      "residual_risk_level": "LOW",
      "mitigation": "Rated burst pressure testing, compliance testing per IEC 60601-1",
      "last_reviewed": "2023-12-15"
    },
    {
      "hazard_id": "HZ-004",
      "hazard_name": "Drug dose variability",
      "harm": "Subtherapeutic elution leading to restenosis",
      "severity": 3,
      "probability": 2,
      "risk_level": "MEDIUM",
      "residual_risk_level": "LOW",
      "mitigation": "Drug content uniformity testing, elution profile QC per batch",
      "last_reviewed": "2023-12-15"
    },
    {
      "hazard_id": "HZ-005",
      "hazard_name": "Nickel hypersensitivity from alloy",
      "harm": "Local tissue inflammation, potential allergic reaction",
      "severity": 2,
      "probability": 2,
      "risk_level": "LOW",
      "residual_risk_level": "LOW",
      "mitigation": "Biocompatibility per ISO 10993, patient screening in IFU",
      "last_reviewed": "2023-12-15"
    },
    {
      "hazard_id": "HZ-006",
      "hazard_name": "Late stent thrombosis",
      "harm": "Myocardial infarction",
      "severity": 5,
      "probability": 1,
      "risk_level": "HIGH",
      "residual_risk_level": "MEDIUM",
      "mitigation": "Dual antiplatelet therapy guidance in IFU, PMCF registry monitoring",
      "last_reviewed": "2023-12-15"
    },
    {
      "hazard_id": "HZ-007",
      "hazard_name": "Stent fracture under fatigue",
      "harm": "In-stent restenosis or vessel perforation",
      "severity": 4,
      "probability": 1,
      "risk_level": "MEDIUM",
      "residual_risk_level": "LOW",
      "mitigation": "400 million cycle fatigue testing, FEA validation, radiopaque visibility",
      "last_reviewed": "2023-12-15"
    },
    {
      "hazard_id": "HZ-008",
      "hazard_name": "Delivery catheter kinking",
      "harm": "Inability to deliver stent, procedure prolongation",
      "severity": 2,
      "probability": 2,
      "risk_level": "LOW",
      "residual_risk_level": "LOW",
      "mitigation": "Trackability testing, braided shaft design, training program",
      "last_reviewed": "2023-12-15"
    }
  ],
  "overall_benefit_risk_conclusion_prior": "Benefits outweigh risks. Device performance within acceptable limits based on 2022 surveillance data. No new safety signals identified. Residual risk profile remains acceptable.",
  "overall_benefit_risk_conclusion_current": "Benefits continue to outweigh risks. No new safety signals identified in 2023 surveillance period. CAPA-001 and CAPA-002 closed with confirmed effectiveness. CAPA-003 open with monitoring ongoing. FSCA-001 completed successfully. Overall residual risk profile unchanged."
}